Cepheid Announces Ce Ivd Release Of First On-Demand Test For Van...

The 45-minute test runs on Cepheid's GeneXpert System, the world's leading HAI molecular platform, and is the first test developed and manufactured by Cepheid AB in Bromma, Sweden.

Husband should recover from valley fever, have lifelong immunity

This is a common illness, affecting an estimated 500,000 or more Americans each year.

Prophylaxis after Exposure to Coxiella burnetii

Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA Abstract Coxiella burnetii is a category B bioterrorism agent.

AdvanDx Receives Fda 510(k) Clearance For Yeast Traffic Light Pna Fish

Main Category: Blood / Hematology Also Included In: Infectious Diseases / Bacteria / Viruses AdvanDx announced it received FDA 510 clearance of the Yeast Traffic Light PNA FISH to identify Candida yeast species ...

AdvanDx, Inc. Receives FDA 510

AdvanDx today announced it received FDA 510 clearance of the Yeast Traffic Light PNA FISH to identify Candida yeast species directly from positive blood cultures.

Phase III U.S. Pivotal Study Results On CSL Biotherapies' Afluria...

Phase III U.S. Pivotal Study Results On CSL Biotherapies' Afluria Published In Vaccine - Influenza Virus Vaccine Main Category: Flu / Cold / SARS Also Included In: Respiratory / Asthma Immune System / Vaccines ...

CSL Biotherapies Announces First Shipments of Afluria Thimerosal-Free ...

Sep 4, 2008 - CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that it has begun shipment of its influenza virus vaccine in the U.S. for the ...

CSL Biotherapies Announces First Shipments of Afluria(R)...

CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes.

Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria Published in Vaccine

Sept. 3, 2008 - Phase III pivotal study findings in the journal Vaccine showed that two formulations of CSL Biotherapies' influenza virus vaccine Afluria elicited an immune response in healthy adults aged 18 - ...

Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria(R) Published in Vaccine

KING OF PRUSSIA, Pa.-- --Phase III pivotal study findings in the journal Vaccine showed that two formulations of CSL Biotherapies ' influenza virus vaccine Afluria elicited an immune response in healthy adults ...